Literature DB >> 955941

Familial iminoglycinuria with normal intestinal absorption of glycine and imino acids in association with profound mental retardation, a possible "cerebral phenotype".

M Statter, A Ben-Zvi, A Shina, R Schein, A Russell.   

Abstract

Spasticity and severe psychomotor retardation in a 2-year-old girl, apparently in expression of chronic progressive encephalopathy, was found in association with prolinuria, hydroxyprolinuria and hyperglycinuria. The pattern and levels of these amino acids in plasma proved to be normal, however, as was their intestinal absorption as well as their concentration in cerebrospinal fluid. The proband appears to be homozygous for iminoglycinuria with an apparent inborn defect of the renal tubular transport system specific to these amino acids. An isolated hyperglycinuria, however, was traced in several obligate heterozygotes in this family. The possibility of a more direct causative link between this anomaly and her clinical manifestations is discussed. Where instances of iminoglycinuria occur in association with cerebral pathology of this type, an analogous impairment of a correspondingly specific cerebral amino acid transport system is postulated.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 955941

Source DB:  PubMed          Journal:  Helv Paediatr Acta        ISSN: 0018-022X


  2 in total

1.  Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters.

Authors:  Stefan Bröer; Charles G Bailey; Sonja Kowalczuk; Cynthia Ng; Jessica M Vanslambrouck; Helen Rodgers; Christiane Auray-Blais; Juleen A Cavanaugh; Angelika Bröer; John E J Rasko
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

2.  Hypertension and impaired glycine handling in mice lacking the orphan transporter XT2.

Authors:  Hui Quan; Krairerk Athirakul; William C Wetsel; Gonzalo E Torres; Robert Stevens; Y T Chen; Thomas M Coffman; Marc G Caron
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.